Q1 2024 Earnings Summary
- Strong Revenue Growth and Increased Annual Guidance: TransMedics reported Q1 2024 total revenue of $96.9 million, representing a 133% growth over Q1 2023 and a 19% sequential increase from Q4 2023. The company increased its annual revenue guidance to $390 million to $400 million, representing 61% to 66% growth over full year 2023 revenue.
- Expansion of Aviation Fleet and Transplant Logistics Services: TransMedics is expanding its aviation fleet, expecting to reach 15 to 20 operational aircraft by year-end and 25 to 30 planes by the end of next year, aiming to cover 80% of total NOP missions. This expansion is expected to increase operational efficiency, reduce costs, and drive revenue growth through increased adoption of their logistics services.
- Launch of New Clinical Programs to Expand OCS Adoption: The company plans to initiate three major clinical programs within the next year to expand the adoption of its Organ Care System (OCS) technology and increase transplant volumes. These programs aim to extend the use of OCS Lung and OCS Heart, including pursuing new FDA indications, which could significantly grow the addressable market and drive future revenue growth.
- Increasing dependence on lower-margin service revenue may pressure overall margins: TransMedics is experiencing an increase in the service component of its revenue mix, which could impact gross margins negatively. The service revenue is expected to rise from 36.7% to between 37% and potentially 39% of total revenue, higher than previously anticipated. Although management expects overall gross margins to improve, the growing proportion of lower-margin service revenue, especially from aviation logistics, might limit margin expansion.
- Operational risks associated with aviation fleet expansion and maintenance: TransMedics plans significant expansion of its aviation fleet to support its National OCS Program (NOP), targeting 15 to 20 operational aircraft by year-end 2024 and 25 to 30 planes by the end of 2025. However, the company acknowledges potential operational challenges, including aircraft maintenance and downtime. Some planes are due for annual service in the second half of the year, which will make them inaccessible and may affect the company's ability to meet its guidance and operational targets.
- Delay in expanding FDA indications and potential competitive risk: TransMedics currently lacks FDA approval for preserving standard criteria DBD (Donation after Brain Death) hearts, limiting access to a segment of the heart transplant market estimated at 900 to 1,200 transplants annually. The company plans to initiate a clinical program for cold perfusion to obtain this indication, but the trial will not start until early 2025 due to the need for a new system and circuitry. This delay could provide an opportunity for competitors to enter the market and capture market share before TransMedics can expand its indications.
-
Strong Revenue Growth
Q: What drove the additional volumes leading to the strong revenue beat?
A: The strong revenue growth was primarily driven by improved clinical outcomes across all organ platforms, particularly in heart and lung. The company's efforts in educating the market and demonstrating better outcomes with their newer use model resonated in the quarter. Additionally, growth in the logistics business helped access cases previously unattainable due to limitations in outside logistics. Fundamentally, the growth is based on clinical outcomes.
-
Guidance and Seasonal Cadence
Q: How should we think about guidance and seasonal cadence for the rest of the year?
A: The company expects modest sequential growth quarter-over-quarter but is cautious due to potential operational challenges such as some planes undergoing annual service and potential seasonality from summer vacations and holidays. They factor these considerations into their guidance and aim to be prudent. They do not expect a down quarter sequentially.
-
Pipeline Impact on DCD Donors
Q: How will the OCS system reduce non-progressing DCD donors in heart, liver, and lung?
A: The company plans to leverage their OCS system over the next 12 to 24 months to reduce the percentage of DCD donors that do not progress. They believe their system is uniquely positioned to address this issue and aim to focus on growing DCD utilization through upcoming clinical programs.
-
Benefits in Fatty Livers
Q: What are the benefits of using OCS warm perfusion in fatty livers?
A: Using OCS warm normothermic perfusion in fatty livers shows clinical superiority compared to cold storage or cold hyper-oxygenated perfusion. Fatty livers are better preserved with warm perfusion because cold storage can cause fat cells to congeal, making the liver less physiologic. The company anticipates presenting data on fatty livers greater than 25% or 30%, which constitutes a sizable portion of donor livers.
-
Aviation Fleet Expansion
Q: What is needed to reach 80% coverage of U.S. cases with company-owned planes?
A: To reach approximately 80% coverage, the company estimates needing between 25 and 30 planes. They plan to end the year with 15 to 20 planes and aim to have between 25 and 30 planes by the end of next year. This expansion will help them demonstrate growth and meet increasing demands.
-
Operating Profit Guidance
Q: Any operating profit guidance for the remainder of the year?
A: While not providing specific guidance, the company is pleased with the strong Q1 results and believes they are on a path to sustainable profit going forward. They are ahead of where they thought they would be at this point.
-
Limiting Cold Perfusion to 6 Hours
Q: Why limit cold perfusion for heart to only 6 hours, especially when competitors go longer?
A: The company chooses to limit cold perfusion to 6 hours because longer durations have been associated with failed trials in Europe. They prioritize patient outcomes and provide a lower-cost solution for the segment below 6 hours. For longer durations, they plan to demonstrate that warm perfusion is a better solution than cold perfusion through new heart programs.
-
Market Penetration and Upcoming Trials
Q: Can you clarify market penetration and details of upcoming trials?
A: Currently, their FDA-approved indication does not cover standard criteria DBD hearts. They plan to obtain a new indication to cover this segment, which represents about 900 to 1,200 transplants based on last year's numbers. They have two heart programs: one focusing on warm perfusion with therapeutic optimization modalities, expected to start before year-end; and one on cold perfusion with a new system, starting in early 2025. The cold perfusion will be pulsatile, a distinguishing feature.
-
Depreciation and Margins of Planes
Q: How does TransMedics depreciate its planes, and what are the aviation margins?
A: The planes are depreciated over 10 years with a 50% residual value. While they haven't detailed the margins of aviation versus service, overall service margin is at 36%, with expectations of improvement. The aviation margin is a bit lower than the service margin.
-
Customer Feedback on Aviation
Q: What feedback have customers provided on TransMedics aviation?
A: Customers have shown positive reception, evidenced by the rapid growth from 0 to 105 customers using TransMedics logistical services. Customers are experiencing better structure, more efficient cost, and improved availability with TransMedics logistics. The company expects to deepen relationships within these accounts.
-
International Market Opportunities
Q: Can you provide an update on international markets and expectations post-ISHLT meeting?
A: There is significant interest in replicating the success of NOP internationally, particularly from major European countries and the Middle East, like Saudi Arabia. The company is focused on establishing NOPs abroad but prioritizes securing reimbursement to ensure their services are paid for. Internationally, they plan to offer clinical support services without logistics and surgical procurement.
-
Guidance Range Details
Q: What's baked into the low and high ends of the guidance range?
A: The company sees opportunities to grow sequentially and believes that deepening relationships with a few centers could help reach the high end of the guidance. The low end reflects a more conservative view on the pace of growth. They are confident in meeting their updated annual revenue guidance of $390 million to $400 million.
-
Product-Service Mix Expectations
Q: How will the product-service mix change throughout the year?
A: The service portion was 36.7% in Q1, and it may increase to between 37% and potentially 39% throughout the year. This slight increase is based on observed outcomes. Despite this shift, they expect overall gross margins to continue improving.